0226 A Novel GABAergic Dietary Supplement Enhances Sleep Quality in Ovariectomized Mice
Devon Bernsley,Kazim Sahin,Ertugrul Kilic,Ahmet Kayhan Korkusuz,Cemal Orhan,Besir Er,James Komorowski
DOI: https://doi.org/10.1093/sleep/zsae067.0226
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Sleep disruptions affect 56% of the population. Sleep disorders are common symptoms facing peri- and post-menopausal women. Ovariectomized rodents are a common study model for research on menopausal symptoms. The primary objective of this investigation was to evaluate the effects of BH_SLP_01 (Bonafide Health Sleep Product) on sleep quality and brain wave patterns in ovariectomized mice. Methods Five female BALB/c mice (age: 8 weeks, body mass: 180±20g) were allocated per treatment arm. After an adaptation period, all mice were ovariectomized (OVX). Treatment groups included caffeine control (control) and caffeine + BH_SLP_01. Both groups were treated with caffeine to induce sleep disturbance. Caffeine (7.5mg/kg) was injected intraperitoneally at the 15th minute of recordings, and second injections (saline or combinations) were performed at the 30th minute (min). Brain electrical activity was monitored and recorded for two hours total using electrocorticography (ECoG). Serum melatonin, serotonin, and dopamine were measured by ELISA. Brain levels of MDA were measured by HPLC and protein concentrations were determined using Western Blot analysis. Study treatments were compared using an ANOVA, Tukey’s post-hoc test, and Student's unpaired t-test. Significance levels were set at < 0.05. Results Analysis of ECoG recording data revealed notable findings. Significant differences in amplitude were seen at 15-30, 45-60, 60-75, and 75-90 min time points for the BL_SLP_01 group compared to control. Significant differences in frequency were seen at 15-30, 30-45, 45-60, 60-75, 75-90, and 90-105 min timepoints for the BH_SLP_01 group compared to control. Additionally, serotonin, dopamine, melatonin, brain MDA, GABA-A R2, GABA-B R1, GABA-B R2, 5-HT1A, GluA1, GluN1, GluN2A, Bax, Bcl-2, and Caspase-3 levels were significantly improved by BH_SLP_01 compared to control (p< 0.05). Conclusion This study provides evidence for the efficacy of BH_SLP_01 to improve impaired sleep in a menopausal model. This conclusion is supported by notable enhancements in sleep architecture demonstrated by ECoG recording data. Furthermore, the results show an upregulation of GABA, glutamine receptors, and natural melatonin, all of which collectively contribute to sleep quality. These findings underscore the potential of BH_SLP_01 as a promising therapeutic intervention for menopausal women experiencing sleep stress and disturbances. Support (if any) Research was supported by Bonafide Health, LLC.
neurosciences,clinical neurology